CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 307 enrolled
Drug / intervention
Isavuconazoledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04550936
NCT04550936N/ACompleted

Patterns of Real-World Isavuconazole Use, Effectiveness, Safety, and Healthcare Resource Utilization-a Retrospective Chart Review Study of Patients With Mucormycosis or Invasive Aspergillosis (PRISMA)

Pfizer·observational·Posted Sep 16, 2020·Updated Dec 9, 2025

In Brief

An observational study evaluating Isavuconazole for Invasive Aspergillosis and Mucormycosis. Completed, enrolled 307 participants across 15 sites in 5 countries.

Detailed Summary

This is a non-interventional medical chart review study aiming to examine the effectiveness, safety, and treatment patterns of isavuconazole in 5 European countries (France, Germany, Italy, Spain, and United Kingdom). Eligible patients are adults who have been treated with isavuconazole in routine practice at participating sites since 15 October, 2015 or since the date of launch in the country if it is after 15 October, 2015 until 30 June, 2019. As this is an observational study, patients will be treated based on the standard of care at the discretion of their physician. No drugs will be supplied for this study and patients will receive treatment through standard local practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, Italy, Spain, United Kingdom
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedSep 16, 2020
Enrollment StartMar 10, 2021
Primary CompletionDec 23, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.8 years ago

Interventions

Isavuconazoledrug

antifungal agent